Video

Mark S. Freedman, HBSc, MSc, MD

Publish date: June 5, 2015

At the 2015 CMSC Annual Meeting, Prof. Mark Freedman discusses recent trial results for teriflunomide.


 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Variation in Brain Iron Levels in MS and CIS
MDedge Neurology
Does Education Status Impact MS Risk?
MDedge Neurology
Factors Linking Optic Neuritis to MS Risk
MDedge Neurology
When Patients Don’t Respond to Interferon-β
MDedge Neurology
Life Expectancy and Multiple Sclerosis
MDedge Neurology
Switching From Natalizumab to Dimethyl Fumarate: Real-World Experience
MDedge Neurology
Alemtuzumab May Suppress Disease Activity for Four Years
MDedge Neurology
Daclizumab HYP May Improve Ambulation and Cognition, Compared With Interferon β-1a
MDedge Neurology
Expert: Don’t discourage pregnancy in MS patients; manage it
MDedge Neurology
Samuel F. Hunter, MD, PhD
MDedge Neurology